- Home
- XEL vs ONC Comparison
XEL vs ONC Comparison
Compare XEL & ONC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XEL
- ONC
- Stock Information
- Founded
- XEL 1909
- ONC 2010
- Country
- XEL United States
- ONC Switzerland
- Employees
- XEL N/A
- ONC N/A
- Industry
- XEL Power Generation
- ONC Biotechnology: Pharmaceutical Preparations
- Sector
- XEL Utilities
- ONC Health Care
- Exchange
- XEL Nasdaq
- ONC Nasdaq
- Market Cap
- XEL 43.3B
- ONC 37.3B
- IPO Year
- XEL N/A
- ONC N/A
- Fundamental
- Price
- XEL $72.61
- ONC $332.27
- Analyst Decision
- XEL Buy
- ONC Strong Buy
- Analyst Count
- XEL 11
- ONC 9
- Target Price
- XEL $77.00
- ONC $335.78
- AVG Volume (30 Days)
- XEL 4.6M
- ONC 365.5K
- Earning Date
- XEL 10-30-2025
- ONC 11-11-2025
- Dividend Yield
- XEL 3.11%
- ONC N/A
- EPS Growth
- XEL 7.56
- ONC N/A
- EPS
- XEL 3.60
- ONC N/A
- Revenue
- XEL $13,957,000,000.00
- ONC $4,562,002,000.00
- Revenue This Year
- XEL $13.05
- ONC $875.58
- Revenue Next Year
- XEL $6.52
- ONC $20.99
- P/E Ratio
- XEL $20.39
- ONC N/A
- Revenue Growth
- XEL 1.28
- ONC 47.33
- 52 Week Low
- XEL $62.12
- ONC $170.99
- 52 Week High
- XEL $74.57
- ONC $351.27
- Technical
- Relative Strength Index (RSI)
- XEL 51.35
- ONC 55.45
- Support Level
- XEL $71.29
- ONC $324.03
- Resistance Level
- XEL $73.72
- ONC $336.80
- Average True Range (ATR)
- XEL 0.98
- ONC 7.81
- MACD
- XEL -0.03
- ONC -0.38
- Stochastic Oscillator
- XEL 54.32
- ONC 66.10
About XEL Xcel Energy Inc.
Xcel Energy manages utilities serving 3.8 million electric customers and 2.2 million natural gas customers in eight states. Its utilities are Northern States Power, which serves customers in Minnesota, North Dakota, South Dakota, Wisconsin, and Michigan; Public Service Company of Colorado; and Southwestern Public Service Company, which serves customers in Texas and New Mexico. It is one of the largest renewable energy suppliers in the US, with more than half of its electricity sales coming from carbon-free energy.
About ONC BeiGene Ltd. American Depositary Shares
Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeOne is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeOne runs global clinical trials with its own team. As of 2024, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 60% of BeOne's revenue.